In summary, this case represents the first known use of crizotinib to target oncogenic ALK overexpression in central‐type PNET arising from an immature teratoma and highlights the importance of obtaining early molecular analyses in these rare tumor entities to determine novel treatment options. This evidence concerns the gene ALK and neoplasm.